You are now leaving ironwoodpharma.com. This link will take you to
a website to which our privacy policy does not apply. You are solely
responsible for your interactions with that website.
You are now leaving ironwoodpharma.com.

Bringing Linaclotide to Patients Around the World

Ironwood has built the team and capabilities to deliver linaclotide to patients in the United States. But our goal is to get this medicine to appropriate patients around the world, in the most efficient way possible, and we’re committed to working with our network of partners both in the U.S. and in other countries to achieve that goal.

NORTH AMERICA

LINZESS®* available in U.S. through 50/50 collaboration

EUROPE

CONSTELLA® available in certain European countries through partnership

CHINA, HONG KONG & MACAU

Under review by regulatory authority for potential approval

JAPAN

LINZESS® available in Japan through partnership

REST OF WORLD

License to develop and market linaclotide in remaining countries